| |
| |
|
| Insider
Information: |
Hillan Kenneth |
| Relationship: |
Chief Therapeutics Off... |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
564,812 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$144,328 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
564,812 |
|
|
| Total
Value |
$144,328 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -47.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Achaogen Inc |
AKAO |
See Remarks, Director |
2018-06-28 |
293,336 |
2015-03-11 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2015-06-04 |
0 |
Premium* |
|
|
Sangamo Biosciences Inc |
SGMO |
Director |
2023-06-01 |
49,600 |
2020-09-09 |
0 |
Premium* |
|
|
23andMe Holding Co. |
ME |
Chief Therapeutics Off... |
2023-06-05 |
221,876 |
2022-02-09 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ME |
23andMe Holding Co. |
Chief Therapeutics Officer |
• – – |
2023-06-05 |
4 |
D |
$2.08 |
$31,922 |
D/D |
(15,347) |
221,876 |
0 |
- |
|
| ME |
23andMe Holding Co. |
Chief Therapeutics Officer |
• – – |
2023-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
44,381 |
237,223 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,900 |
49,600 |
0 |
- |
|
| ME |
23andMe Holding Co. |
Chief Therapeutics Officer |
• – – |
2023-05-20 |
4 |
D |
$1.94 |
$8,978 |
D/D |
(4,628) |
192,842 |
0 |
- |
|
| ME |
23andMe Holding Co. |
Chief Therapeutics Officer |
• – – |
2023-02-20 |
4 |
D |
$2.87 |
$15,662 |
D/D |
(5,457) |
191,705 |
0 |
- |
|
| ME |
23andMe Holding Co. |
Chief Therapeutics Officer |
• – – |
2022-11-20 |
4 |
D |
$2.99 |
$13,838 |
D/D |
(4,628) |
197,162 |
0 |
- |
|
| ME |
23andMe Holding Co. |
Chief Therapeutics Officer |
• – – |
2022-08-24 |
4 |
S |
$3.64 |
$31,861 |
D/D |
(8,753) |
196,083 |
0 |
% |
|
| ME |
23andMe Holding Co. |
Chief Therapeutics Officer |
• – – |
2022-08-20 |
4 |
D |
$3.33 |
$15,411 |
D/D |
(4,628) |
204,836 |
0 |
- |
|
| ME |
23andMe Holding Co. |
Chief Therapeutics Officer |
• – – |
2022-06-01 |
4 |
D |
$2.82 |
$13,048 |
D/D |
(4,627) |
209,464 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
Director |
– • – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
35,700 |
0 |
- |
|
| ME |
23andMe Holding Co. |
Head of Therapeutics |
• – – |
2022-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
214,091 |
214,091 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,200 |
23,200 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
Director |
– • – |
2020-09-09 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
0 |
- |
|
| AKAO |
Achaogen Inc |
See Remarks |
• • – |
2018-06-28 |
4 |
OE |
$3.65 |
$1,084,807 |
D/D |
177,935 |
293,336 |
0 |
- |
|
| AKAO |
Achaogen Inc |
See Remarks |
• • – |
2018-06-26 |
4 |
S |
$9.59 |
$7,135 |
D/D |
(744) |
115,401 |
0 |
- |
|
| AKAO |
Achaogen Inc |
See Remarks |
• • – |
2018-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
2,150 |
116,145 |
0 |
- |
|
| AKAO |
Achaogen Inc |
See Remarks |
• • – |
2018-03-13 |
4 |
S |
$11.74 |
$32,109 |
D/D |
(2,735) |
95,151 |
0 |
- |
|
| AKAO |
Achaogen Inc |
See Remarks |
• • – |
2018-02-21 |
4 |
S |
$10.67 |
$49,146 |
D/D |
(4,606) |
97,886 |
0 |
- |
|
| AKAO |
Achaogen Inc |
See Remarks |
• • – |
2018-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
17,100 |
112,251 |
0 |
- |
|
| AKAO |
Achaogen Inc |
Chief Executive Officer |
• • – |
2017-03-14 |
4 |
S |
$26.58 |
$81,840 |
D/D |
(3,079) |
98,422 |
0 |
- |
|
| AKAO |
Achaogen Inc |
Chief Executive Officer |
• • – |
2017-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
101,501 |
0 |
- |
|
| AKAO |
Achaogen Inc |
Chief Executive Officer |
• • – |
2017-02-21 |
4 |
S |
$22.76 |
$38,601 |
D/D |
(1,696) |
61,501 |
0 |
- |
|
| AKAO |
Achaogen Inc |
Chief Executive Officer |
• • – |
2017-01-26 |
4 |
S |
$16.78 |
$24,012 |
D/D |
(1,431) |
63,197 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2016-09-01 |
4 |
D |
$32.00 |
$39,584 |
D/D |
(1,237) |
2,250 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2016-09-01 |
4 |
D |
$32.00 |
$72,000 |
D/D |
(2,250) |
0 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
